Fiche du document
2017
- doi: 10.1007/978-1-4939-6445-1_5
- issn: 1064-3745
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1007/978-1-4939-6445-1_5
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/27718186
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1940-6029
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_AF425E56083A7
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
Phospholipid vesiclesCiter ce document
L. Brunner et al., « QS-21 Adjuvant: Laboratory-Scale Purification Method and Formulation Into Liposomes. », Serveur académique Lausannois, ID : 10.1007/978-1-4939-6445-1_5
Métriques
Partage / Export
Résumé
QS-21, a saponin extracted from the tree Quillaja saponaria Molina, is a vaccine adjuvant which has been shown to elicit robust antibody and cell-mediated immune responses in a variety of preclinical and clinical studies [1]. Its purification from the natural source is a lengthy and difficult process. The commercially available saponin mixture Quil-A® is a fraction of the bark extract containing a variety of saponins, including QS-21. In order to facilitate access to QS-21 at laboratory-scale amounts, we propose here a method of purification of QS-21 starting from Quil-A®. In addition, we describe a protocol to appropriately formulate QS-21 into cholesterol-containing, neutral liposomes which are known to decrease QS-21's hemolytic activity while retaining the adjuvant effect. Methods for the physicochemical characterization of purified QS-21 and of the QS-21/liposome formulations are also described.